• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel anti-cancer stem cell therapeutic strategies targeting oxidative phosphorylation

Research Project

Project/Area Number 20K07631
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionYamagata University

Principal Investigator

Okada Masashi  山形大学, 医学部, 准教授 (70512614)

Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywordsがん幹細胞 / 酸化的リン酸化 / OXPHOS / ドラッグリポジショニング / 代謝 / 分化誘導 / 分化 / 葉酸代謝
Outline of Research at the Start

腫瘍の発生・維持にはがん幹細胞 (CSC) が中心的な役割を果たしているがその制圧は未だ困難である。我々は、CSCを非がん幹細胞化させる分化誘導療法を報告してきたが、分化誘導療法は腫瘍中のCSCが一定数以内であれば完全消滅も期待できるため、予め腫瘍中のCSC数を減じる手段と組合わせればより有効であると考えられた。加えて、CSCではOXPHOS活性が高く生存に必須で治療標的となり得ること、OXPHOS抑制によりCSC数を減少可能であることを報告してきた。そこで本研究では、CSCに対する新規OXPHOS阻害薬を探索し、我々が開発したCSC分化誘導薬と併用する新規CSC標的治療モデルの創出を目指す。

Outline of Final Research Achievements

Cancer stem cells (CSCs) play pivotal roles in the development and maintenance of tumors. Although various therapies/drugs against CSCs have been developed, their suppression remains difficult. We performed differential analyses between CSCs and isogenic non-CSCs to develop CSC-targeted therapies. In this study, we show that the lipid accumulation in the lipid droplet and its turnover are essential for the maintenance of stemness. And we revealed that CSCs have higher OXPHOS and folate metabolisms than non-CSCs, and their inhibition is lethal in CSCs. Moreover, we indicated that the combination treatment of a CSC-differentiation inducer developed in our previous studies and a CSC-killing drug described above is a promising CSC-targeting approach.

Academic Significance and Societal Importance of the Research Achievements

本研究から、CSCにはnon-CSCと比較して様々な特異的脆弱性が存在し、それらを標的とすることでCSCを機能的もしくは物理的に殺傷することで腫瘍中のCSC数を減少させうること、また、CSC殺傷薬とCSC分化誘導薬を併用がより腫瘍中のCSC数を減らすことを明らかにしたことは、これらのCSC標的治療法が非常に有望であることを示している。特に本課題にて我々が見出した一部のCSC標的薬はヒトに対して安全性情報がある薬剤をドラッグリポジショニングの手法により流用したものであるため、臨床応用により踏み込みやすく社会的意義も非常に高いことがわかる。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (19 results)

All 2023 2022 2021 2020

All Journal Article (18 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 18 results,  Open Access: 15 results) Presentation (1 results)

  • [Journal Article] CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells2023

    • Author(s)
      Togashi Keita、Suzuki Shuhei、Mitobe Yuta、Nakagawa-Saito Yurika、Sugai Asuka、Takenouchi Senri、Sugimoto Masahiko、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      Cancers

      Volume: 16 Issue: 1 Pages: 118-118

    • DOI

      10.3390/cancers16010118

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells2023

    • Author(s)
      Mitobe Yuta、Suzuki Shuhei、Nakagawa-Saito Yurika、Togashi Keita、Sugai Asuka、Sonoda Yukihiko、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      Cancers

      Volume: 15 Issue: 17 Pages: 4326-4326

    • DOI

      10.3390/cancers15174326

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo2023

    • Author(s)
      Mitobe Yuta、Suzuki Shuhei、Nakagawa-Saito Yurika、Togashi Keita、Sugai Asuka、Sonoda Yukihiko、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      Biomedicines

      Volume: 11 Issue: 7 Pages: 1967-1967

    • DOI

      10.3390/biomedicines11071967

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Domatinostat Targets the FOXM1?Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents2023

    • Author(s)
      Nakagawa-Saito Yurika、Mitobe Yuta、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 24 Issue: 13 Pages: 10817-10817

    • DOI

      10.3390/ijms241310817

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.2023

    • Author(s)
      Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Kitanaka C, Okada M.
    • Journal Title

      Anticancer Res.

      Volume: 3 Issue: 3 Pages: 1131-1138

    • DOI

      10.21873/anticanres.16258

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.2022

    • Author(s)
      Mitobe Y, Nakagawa-Saito Y, Togashi K, Suzuki S, Sugai A, Matsuda KI, Sonoda Y, Kitanaka C, Okada M.
    • Journal Title

      Anticancer Res.

      Volume: 10 Issue: 10 Pages: 4727-4733

    • DOI

      10.21873/anticanres.15977

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties2022

    • Author(s)
      Okada Masashi、Nakagawa-Saito Yurika、Mitobe Yuta、Sugai Asuka、Togashi Keita、Suzuki Shuhei、Kitanaka Chifumi
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 23 Issue: 15 Pages: 8785-8785

    • DOI

      10.3390/ijms23158785

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny2022

    • Author(s)
      Nakagawa-Saito Yurika、Saitoh Shinichi、Mitobe Yuta、Sugai Asuka、Togashi Keita、Suzuki Shuhei、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 23 Issue: 15 Pages: 8084-8084

    • DOI

      10.3390/ijms23158084

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts2021

    • Author(s)
      Okada Masashi、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Yamamoto Masahiro、Kitanaka Chifumi
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 22 Issue: 21 Pages: 11633-11633

    • DOI

      10.3390/ijms222111633

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax2021

    • Author(s)
      Yamamoto Masahiro、Sanomachi Tomomi、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Seino Shizuka、Sato Atsushi、Okada Masashi、Kitanaka Chifumi
    • Journal Title

      Neuro-Oncology Advances

      Volume: 3 Issue: 1 Pages: 1-11

    • DOI

      10.1093/noajnl/vdab148

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction2021

    • Author(s)
      Suzuki Shuhei、Yamamoto Masahiro、Sanomachi Tomomi、Togashi Keita、Sugai Asuka、Seino Shizuka、Yoshioka Takashi、Okada Masashi、Kitanaka Chifumi
    • Journal Title

      Life

      Volume: 11 Issue: 9 Pages: 885-885

    • DOI

      10.3390/life11090885

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin2021

    • Author(s)
      SUZUKI SHUHEI、YAMAMOTO MASAHIRO、SANOMACHI TOMOMI、TOGASHI KEITA、SEINO SHIZUKA、SUGAI ASUKA、YOSHIOKA TAKASHI、OKADA MASASHI、KITANAKA CHIFUMI
    • Journal Title

      Anticancer Research

      Volume: 41 Issue: 9 Pages: 4321-4331

    • DOI

      10.21873/anticanres.15237

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma2021

    • Author(s)
      Yamamoto Masahiro、Sanomachi Tomomi、Suzuki Shuhei、Uchida Hiroyuki、Yonezawa Hajime、Higa Nayuta、Takajo Tomoko、Yamada Yuki、Sugai Asuka、Togashi Keita、Seino Shizuka、Okada Masashi、Sonoda Yukihiko、Hirano Hirofumi、Yoshimoto Koji、Kitanaka Chifumi
    • Journal Title

      Neuro-Oncology

      Volume: XX Issue: 6 Pages: 1-10

    • DOI

      10.1093/neuonc/noab015

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties.2021

    • Author(s)
      Kuramoto K, Yamamoto M, Suzuki S, Togashi K, Sanomachi T, Kitanaka C, Okada M.
    • Journal Title

      Genes (Basel)

      Volume: 12(1) Issue: 1 Pages: 99-99

    • DOI

      10.3390/genes12010099

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1?JNK axis2020

    • Author(s)
      Suzuki Shuhei、Okada Masashi、Sanomachi Tomomi、Togashi Keita、Seino Shizuka、Sato Atsushi、Yamamoto Masahiro、Kitanaka Chifumi
    • Journal Title

      Journal of Biological Chemistry

      Volume: 295 Issue: 52 Pages: 18328-18342

    • DOI

      10.1074/jbc.ra120.015223

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.2020

    • Author(s)
      Togashi K, Okada M, Suzuki S, Sanomachi T, Seino S, Yamamoto M, Yamashita H, Kitanaka C.
    • Journal Title

      Anticancer Res.

      Volume: 40(9) Issue: 9 Pages: 4961-4968

    • DOI

      10.21873/anticanres.14499

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing2020

    • Author(s)
      Suzuki Shuhei、Yamamoto Masahiro、Sanomachi Tomomi、Togashi Keita、Sugai Asuka、Seino Shizuka、Okada Masashi、Yoshioka Takashi、Kitanaka Chifumi
    • Journal Title

      Biomedicines

      Volume: 8 Issue: 8 Pages: 273-273

    • DOI

      10.3390/biomedicines8080273

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells2020

    • Author(s)
      Kuramoto Kenta、Yamamoto Masahiro、Suzuki Shuhei、Sanomachi Tomomi、Togashi Keita、Seino Shizuka、Kitanaka Chifumi、Okada Masashi
    • Journal Title

      The FEBS Journal

      Volume: Epub ahead of print Issue: 10 Pages: 2023-2036

    • DOI

      10.1111/febs.15187

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1- JNK axis2021

    • Author(s)
      Masashi Okada, Shuhei Suzuki, Tomomi Sanomachi, Keita Togashi, Shizuka Seino, Atsushi Sato, Masahiro Yamamoto, and Chifumi Kitanaka
    • Organizer
      第94回 生化学大会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi